Castle biosciences announces publication of study demonstrating the integration of decisiondx®-melanoma and clinicopathologic factors provides optimized, personalized survival prognoses for patients with cutaneous melanoma

Friendswood, texas--(business wire)---- $cstl #cstl--castle announced the publication of a study validating the performance of decisiondx®-melanoma's proprietary algorithm, i31-ror.
CSTL Ratings Summary
CSTL Quant Ranking